US Stock MarketDetailed Quotes

KPRX Kiora Pharmaceuticals

Watchlist

3.2200
-0.0700-2.13%

Close Nov 18 16:00 ET

3.2200
0.00000.00%

Post 20:01 ET

9.66MMarket Cap3.07P/E (TTM)

Kiora Pharmaceuticals Stock Forum

Jaguar8

Nov 10 19:19

Fair ER Friday. Low float. May get pumped. Play only with buy pressure

$Kiora Pharmaceuticals (KPRX.US)$

Jaguar8

Nov 8 12:32

NEWS ER

$Kiora Pharmaceuticals (KPRX.US)$
Kiora Pharmaceuticals (NASDAQ: KPRX)reported Q3 2024 financial results and pipeline updates. The company received approval for ABACUS-2, a Phase 2 study of KIO-301 for retinitis pigmentosa, and finalized the Phase 2 KLARITY trial design for KIO-104. Financial position remains strong with $29.0 million in cash and equivalents, plus $1.8 million in collaboration receivables from Théa partnership. Q3 net loss was $3.4 million, improved from $5.8 million in Q3...

Trytosaveabit

Oct 29 06:03

News

$Kiora Pharmaceuticals (KPRX.US)$ Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

Stock_Drift

Oct 28 10:05

Low Floats. 11:03am 10/28

$CCSC Technology International (CCTG.US)$ $Ascent Solar Technologies (ASTI.US)$ $China SXT Pharmaceuticals (SXTC.US)$ $Prestige Wealth (PWM.US)$ $Kiora Pharmaceuticals (KPRX.US)$ $Wang & Lee Group (WLGS.US)$ $Avalon GloboCare (ALBT.US)$ $Safe Pro Group (SPAI.US)$ $Safe & Green Development (SGD.US)$ $AgEagle Aerial Systems (UAVS.US)$ $Top Wealth Group Holding (TWG.US)$ $Greenlane (GNLN.US)$ $Healthcare Triangle (HCTI.US)$
📊⚡️📊

Trytosaveabit

Sep 11 06:49

New form 4!

$Kiora Pharmaceuticals (KPRX.US)$ 4: Statement of changes in beneficial ownership of securities-Director Shapiro Aron bought 3K shares at 3.60 PS
SEC· 41 mins ago

Trytosaveabit

Jun 13 15:55

Insider buys

$Kiora Pharmaceuticals (KPRX.US)$ Officer Strem Brian M. purchased 3,000 shares of common stock on Jun 13, 2024 at an average price of $4.999 for a total value of $14,997.
Director Parsons Erin purchased 5,260 shares of common stock on Jun 13, 2024 at an average price of $4.88 for a total value of $25,668.8.

Trytosaveabit

Jun 10 19:01

Watching for post R/S movement??

$Kiora Pharmaceuticals (KPRX.US)$ In the world of R/S’s lately. This is gettin a baby R/S! Earnings was very nice and who knows? It hit ATL/52wk low on Friday.That makes a big ole bottom! Hehehe! Likes me some bottoms. Lets see if the higher price from R/S can actually bring some interest from the market in the next few day post R/S? Have vol/price alerts set. If i see a proper chart set up? Ill give it a shot if it presents!

TonyMan

May 10 07:34

$Kiora Pharmaceuticals (KPRX.US)$A parade of solid news but this stock does not pop. I guess institutions have not adopted this stock. I can only guess.

Jaguar8

May 6 06:05

$Kiora Pharmaceuticals (KPRX.US)$
NEWS
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa

Trytosaveabit

Apr 11 06:32

Update

$Kiora Pharmaceuticals (KPRX.US)$ Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
Thu, Apr 11, 2024
Encinitas, California--(Newsfile Corp. - April 11, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has received grant funding from the Choroideremia Research Foundation (CRF) in support of validating functional vision assessments for pat...

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data